An observational study in Clinician Attitudes About PrEP, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by University of North Carolina, Chapel Hill · Observational
This is a three phase study designed to examine clinician behaviors with regard to recommending and prescribing pre-exposure prophylaxis (PrEP) as a primary Human Immunodeficiency Virus (HIV) prevention strategy, and to identify knowledge-related and attitudinal factors associated with these behaviors. Each phase consists of the following:
Phase 1: Semi-structured face-to-face or telephone interviews of ATN-affiliated clinicians. Approximately 10 clinicians will be interviewed.
Phase 2: Development of a new theory-based survey instrument and cognitive interview testing of this survey. Approximately five clinicians (of those who participated in Phase 1) will be interviewed.
Phase 3: Administration of the newly developed survey to ATN-affiliated clinicians. Approximately 60 clinicians will be interviewed.
University of North Carolina, Chapel Hill is the lead sponsor of 1,340 studies on the registry; 133 are open to participants now.
Of its 155 completed or terminated interventional studies of FDA-regulated products, 136 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
ATN-affiliated clinicians (including physicians, nurse practitioners, and physician assistants) who EITHER 1) provide care for HIV-infected and HIV-uninfected adolescents OR 2) provide care to HIV-infected adolescents only.
Exclusion Criteria:
* Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians. * The total duration of Phase 1 is expected to last approximately nine months, including data analysis.
* Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1). * The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey.
* Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians. * The total duration of Phase 3 will last approximately six to nine months.
Explore clinician attitudes and prescribing behaviors in MSM and heterosexually active adults
Explore clinician attitudes and prescribing behaviors with regard to the use of PrEP in men who have sex with men (MSM) and heterosexually active adults as described in the current CDC guidelines, as well as in MSM and heterosexually active adolescents, who are not specifically covered by the guidelines
Time frame: 2 years
Identify factors associated with prescribing PrEP
Identify factors associated with prescribing PrEP, in a sample of clinicians who provide care to HIV-infected adolescents alone OR to HIV-infected and HIV-uninfected adolescents.
Time frame: 2 years
Explore clinician attitudes toward the use of PrEP in potential target populations other than MSM and heterosexually active adults.
Time frame: 2 years
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill